Trial Profile
Preventing meningitis in young people after infant immunisation: effect of a single meningococcal 4CMenB vaccine booster over 10 years of age
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Therapeutic Use
- 10 Jun 2022 Results published in the Vaccine
- 15 May 2018 New trial record
- 10 May 2018 Status changed from recruiting to active, no longer recruiting.